Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Airbus Joins Air India A320 Altitude Drop Probe 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
ADNOC Gas Targets Up to $4B Profit in 2026 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
SAN DIEGO, Feb. 20, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CrownBio, a leader in the field of preclinical immuno-oncology research, offers a CAR T-cell platform for proof-of-concept and therapeutic efficacy validation. Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents. The addition of bioluminescence imaging (BLI) for non-invasive evaluation of systemic and orthotopic tumor progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
“We are committed to delivering innovative services to help our clients’ develop improved cancer therapeutics,” said Dr. Rajendra Kumari, CrownBio’s Chief Scientific Officer, UK. “Our non-invasive BLI capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents.”
Learn more about CrownBio’s CAR T-cell evaluation platform at https://www.crownbio.com/oncology/immuno-oncology/car-t-cell-therapy-models/
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
